Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
the fact that pps held, showed a possible good entry with some upside.
interesting play to keep an eye on in the am.
gl
That is a beautiful chart except for the guy that bought at .04......:(
gl
good article with limited bs.
I do like the (IRWD) Ironwood Approval decision date: June 8, 2012.
slightly distressed at this time with there leagl isssues.
but the prelimin data looks good.
In Phase I trials reported in January 2009 in The American Journal of Gastroenterology, researchers found that 42 patients with chronic constipation who participated in the randomized, double-blind, placebo-controlled study experienced relief and that the medication was well tolerated.[2] In results of a first round of Phase III clinical trials announced in September 2010, Ironwood studied approximately 800 patients over 12 weeks who were given linaclotide or a placebo in a randomized double-blind trial. 34% of those receiving linaclotide experienced relief of pain and constipation, compared to 21% of patients who had taken the placebo. 50% of those receiving linaclotide saw a significant reduction in pain, versus 37% with the placebo, with pain reduction starting in the first week on the medication. 6% of patients left the study after experiencing diarrhea, the most common reported side effect
Under a partnership agreement announced in 2007 between Forest Laboratories and Microbia (as Ironwood was then known), Forest would pay $70 million in licensing fees towards the development of linaclotide, with profits shared between the two companies.[3] Distribution rights in the United States will be shared with Forest Laboratories, with Almirall distributing linaclotide in Europe and Astellas Pharma in Asia.
Play too keep an eye on, over the next couple of months for entry when it bottoms out.
gl
22 Hot Drugs Facing FDA Approval in 2012
http://www.thestreet.com/print/story/11324723.html
11/29/11 - 08:55 AM EST
Updated with three additional drug approval decision dates.
BOSTON (TheStreet) -- Here's your first look at the biotech and pharmaceutical companies with pending FDA drug approval decisions in 2012.
The calendar on the following pages captures nearly two-dozen U.S. regulatory events -- FDA drug approvals and advisory panels -- expected between December 2011 and July 2012. As every savvy biotech investor and trader knows, the volatility in biotech and drug stocks ramps significantly as U.S. regulators weigh whether to approve or reject new drugs.
Among the highlights from the 2012 FDA drug-approval calendar that should be of most interest to bio-pharma investors: A first-quarter FDA advisory panel that will once again tackle the thorny issue of obesity-drug safety, including Vivus'(VVUS) Qnexa; approval decisions for novel inhaled medicines from Alexza Pharmaceuticals(ALXA) and MAP Pharmaceuticals(MAPP); and the fifth (!!) attempt at approval for Discovery Labs'(DSCO) lung therapy for premature infants.
Biotech and drug stocks below are listed in chronological order based on the closest regulatory catalyst.
Affymax(AFFY)
Drug/indication:peginesatide for anemia in kidney dialysis patients.
FDA advisory panel: Dec. 7, 2011
Approval decision date:March 27, 2012
Peginesatide, injected once monthly, aims to compete against Amgen's(AMGN) Epogen ($2.5 billion in 2010 sales) as a treatment for anemia in patients with chronic kidney disease, although peginesatide use would be limited to sicker kidney dialysis patients only. Amgen recently signed long-term Epogen supply contracts with the two largest kidney dialysis clinics in the U.S.
Pfizer(PFE)
Drug/indication:Inlyta (axitinib) for kidney cancer
FDA advisory panel: Dec. 7, 2011
Approval decision date: Feb-April 2012
Alexza Pharmaceuticals(ALXA)
Drug/indication:Adasuve for agitation related to schizophrenia
FDA advisory panel: Dec. 12, 2011
Approval decision date: Feb. 4, 2012
Adasuve uses Alexza's proprietary Staccato inhaler system to deliver the anti-agitation medicine loxapine directly into the lungs where it gets into the bloodstream and begins to work quickly. The FDA advisory panel is expected to focus much of its attention on the potential side effects and safety issues related to delivering Adasuve into patients' lungs.
FDA initially rejected Adasuve in October 2010 due to concerns over lung safety. Alexza resubmitted the drug to FDA last August.
Vivus(VVUS), Arena Pharmaceuticals(ARNA) and Orexigen Therapeutics(OREX)
Drugs/indication: Qnexa, lorcaserin and Contrave for obesity.
FDA advisory panel: First quarter 2012 (exact date not yet disclosed.)
FDA held advisory panels to review all three of these controversial weight-loss drugs in 2010. FDA subsequently rejected all three drugs. In 2012, Vivus and its obesity drug competitors are back for another shot, and FDA will once again bring together a group of outside experts to weigh the pros and cons of treating obesity with a pill.
Biogen Idec(BIIB) and Elan (ELN)
Drug/indication:Update to the Tysabri prescribing label
Approval decision date: Jan. 20, 2012
The Tysabri label update will include information about the anti-JC virus antibody status as a factor to help stratify the risk of progressive multifocal leukoencephalopathy (PML). Doctors can use to test to determine which multiple sclerosis patients are at low or high risk for PML, a serious, potentially fatal brain infection caused by Tysabri.
Columbia Labs(CBRX) and Watson Pharmaceuticals(WPI)
Drug/indication:progesterone vaginal gel for risk reduction of preterm birth.
FDA advisory panel: Jan. 20, 2012
Approval decision date:Feb. 26, 2012
Amylin Pharmaceuticals(AMLN)
Drug/indication: Bydureon for diabetes
Approval decision date: Jan. 27, 2012
This is the second shot at approval for Bydureon, a once-weekly injectable medicine for the treatment of Type 2 diabetes. Amylin recently split with its long-time marketing partner Eli Lilly(LLY). Alkermes(ALKS) retains its royalty split on Bydureon sales.
Bristol-Myers Squibb(BMY)
Drug/indication: dapagliflozin for diabetes
Approval decision date: Jan. 27, 2012
Pfizer(PFE) and Protalix Biotherapeutics(PLX)
Drug/indication: Uplyso for Gaucher's disease.
Approval decision date: Feb. 1, 2012
FDA has twice-rejected Uplyso due to manufacturing and quality control issues. If approved this time around, Uplyso will compete against Sanofi/Genzyme's(SNY) Cerezyme and Shire's Vpriv.
Teva(TEVA) and BioSante Pharmaceuticals(BPAX)
Drug/indication: Bio-T-Gel for hypogonadism
Approval decision date: Feb. 14, 2012
Bio-T-Gel is a once-daily gel used to treat low testosterone in men.
Corcept Pharmaceuticals(CORT)
Drug/indication: Corlux for Cushing's Syndrome.
Approval decision date: Feb. 17, 2012
FDA will not convene an advisory panel to review Corlux.
Discovery Labs(DSCO)
Drug/indication: Surfaxin for respiratory distress syndrome in premature infants.
Approval decision date: March 6, 2012
This is Discovery's fifth attempt at convincing FDA to approve Surfaxin.
Roche(RHHBY) and Curis(CRIS)
Drug/indication: Vismodegib for advanced basal cell carcinoma.
Approval decision date: March 8, 2012.
MAP Pharmaceuticals(MAPP)
Drug/indication: Levadex for migraines
Approval decision date: March 26, 2012
Levadex is an inhaled migraine drug. FDA has not yet announced whether it intends to hold an advisory panel to review Levadex.
Chelsea Therapeutics(CHTP)
Drug/indication: Northera for orthostatic hypotension
Approval decision date: March 28, 2012
Pfizer(PFE) and Bristol-Myers Squibb(BMY)
Drug/indication: Eliquis for prevention of stroke and blood clots in patients with atrial fibrilation.
Approval decision date: March 28, 2012
Onyx Pharmaceuticals(ONXX)
Drug/indication: Carfilzomib for multiple myeloma
Approval decision date: March 28, 2012 (estimated, not confirmed, based on Sept. 28, 2011 filing date.
FDA accepted the carfilzomib filing on Nov. 28 but has not yet set a specific approval decision date. I'm assuming a six-month priority review because carfilzomib is a cancer drug.
Vivus(VVUS)
Drug/indication: Qnexa for obesity
Approval decision date: April 17, 2012
FDA rejected Qnexa initially in 2010 due to safety concerns.
Vertex Pharmaceuticals(VRTX)
Drug/indication: Kalydeco for cystic fibrosis
Approval decision date: April 19, 2012
Kalydeco is the first drug to treat the underlying cause of cystic fibrosis in patients with a specific genetic defect.
Cell Therapeutics(CTIC)
Drug/indication: pixantrone for non-Hodgkin's lymphoma
Approval decision date: April 2012 (Specific date unknown.)
Cell Therapeutics appealed the FDA's 2009 decision to reject pixantrone, setting up the drug's second chance at U.S. approval.
Amgen(AMGN)
Drug/indication: Xgeva for prevention of bone metastases from prostate cancer.
Approval decision date: April 26, 2012
VVUS(VVUS)
Drug/indication: Avanafil for erectile dysfunction.
Approval decision date: April 29, 2012
Merck(MRK) and Ariad Pharmaceuticals(ARIA)
Drug/indication: ridaforolimus for sarcoma.
Approval decision date: June 5, 2012
Ironwood Pharmaceuticals(IRWD)
Drug/indication: linaclotide for irritable bowel syndrome.
Approval decision date: June 8, 2012
Amarin(AMRN)
Drug/indication: AMR101 for dyslipidemia.
Approval decision date: July 26, 2012
Received a CD from investor relations with respnses to my questions(per form letter).
will update you guys when reviewed.
will call the company/IR when the cd is reviewed.
gl
look to renter in the low $20s.
depends on the L2 over the next few days.
gl
ECYT shortage of doxil resolved. should enable Ecyt to move forward with additional trial and EU review sooner than expected.
http://yourlife.usatoday.com/health/story/2012-02-20/New-source-found-for-cancer-drug-Doxil-in-short-supply/53181806/1
gl
greek bailout finalized.
http://finance.yahoo.com/news/second-greek-bailout-reach-funding-gap-narrows-015256172.html
BRUSSELS (Reuters) - Euro zone finance ministers approved on Tuesday a second bailout for debt-laden Greece that will resolve Athens' immediate repayment needs but seems unlikely to revive the nation's shattered economy.
After a marathon 12 hours of talks through the night, euro zone officials said ministers had agreed measures to cut Greece's debt to around 121 percent of gross domestic product by 2020, close to their original target of 120, after negotiators for private bondholders offered to accept a bigger loss to help plug the funding gap.
Agreement on a 130-billion-euro rescue package with strict conditions attached will help draw a line under months of uncertainty that has shaken the currency bloc, and avert an imminent bankruptcy.
"The financial volume (of the Greek package) is 130 billion euros and debt-to-GDP (will be) 121 percent. Now it's down to work on the statement," one official involved in the negotiations told Reuters. Another confirmed the two figures.
The euro jumped almost half a cent, reversing earlier losses, after Reuters reported a deal had been struck.
A report prepared for ministers by EU, European Central Bank and IMF experts, obtained exclusively by Reuters, said Greece would need extra relief to cut its debts near to the official debt target 2020 given the ever-worsening state of its economy.
If Athens did not follow through on economic reforms and savings, its debt could hit 160 percent by that date.
"Given the risks, the Greek program may thus remain accident-prone, with questions about sustainability hanging over it," the 9-page confidential report said, highlighting the fact that Greece's problems are far from over.
The accord will enable Greece to launch a bond swap with private investors to help reduce and restructure Athens' vast debts, put it on a more stable financial footing and keep it inside the 17-country euro zone.
Greece will have around 100 billion euros of debt written off as banks and insurers will swap bonds they hold for longer-dated securities that pay a lower coupon.
Private sector holders of Greek debt are expected to take losses of 53.5 percent or more on the nominal value of their bonds as part of a debt exchange that will reduce Greece's debts by around 100 billion euros.
Previously they had agreed to take a 50 percent nominal writedown, which equated to around a 70 percent loss on the net present value of the bonds.
The debt sustainability report delivered to ministers last week showed that without further measures Greek debt would only fall to 129 percent by 2020.
The IMF had said if the ratio was not cut to near 120 percent, it may not have been able to help finance the bailout.
Diplomats and economists say the deal may only delay a deeper default by a few months. A turnaround could take as much as a decade, a prospect that brought thousands of Greeks onto the streets to protest against austerity measures on Sunday.
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
Euro zone crisis in graphics http://r.reuters.com/hyb65p
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
DOUBTS OVER COMMITMENT
Skeptics question whether a new Greek government will stick to the deeply unpopular program after elections due in April, and believe Athens could again fall behind in implementation, prompting exasperated lenders to pull the plug once the euro zone has stronger financial firewalls in place.
While there are doubts in Germany and other countries that Greece will be able to meet its commitments, including implementing 3.3 billion euros of spending cuts and tax increases, the threat of contagion from a chaotic Greek default always made a deal more likely than not, no matter how tortuous the negotiations.
Greek Prime Minister Lucas Papademos, International Monetary Fund Managing Director Christine Lagarde and ECB President Mario Draghi all attended the Brussels talks in a sign they were likely to be decisive.
The private creditor bond exchange is expected to launch on March 8 and complete three days later, Athens said on Saturday. That means a 14.5-billion-euro bond repayment due on March 20 would be restructured, allowing Greece to avoid default.
The vast majority of the funds in the 130-billion-euro program will be used to finance the bond swap and ensure Greece's banking system remains stable: 30 billion euros will go to "sweeteners" to get the private sector to sign up to the swap, 23 billion will go to recapitalize Greek banks.
A further 35 billion will allow Greece to finance the buying back of the bonds, and 5.7 billion will go to paying off the interest accrued on the bonds being traded in. Next to nothing will go directly to help the Greek economy.
Those numbers could change in the final analysis given the scramble to meet the overall objective of reducing Greece's debts from 160 percent of GDP to around 120 by 2020.
Earlier, euro zone sources said national central banks in the currency bloc could restructure Greek bonds held in their investment portfolios in the same way as private investors, cutting Athens' debt by 3.5 percentage points.
If the ECB were to forego profits on its Greek holdings, that would raise another 5.5 percentage points of GDP, the report showed.
The deal will provide immediate relief to Athens and financial markets but no one is pretending it will end Greece's problems. Figures last week showed its economy shrank 7 percent year-on-year in the last quarter of 2011, much more than expected, with further cuts likely to make matters worse.
The troika of European Commission, ECB and IMF, responsible for monitoring Greece's reform progress, carries out quarterly reviews and could decide Athens is not meeting its commitments at any one of them.
BUT, will we revisit this again?
The first details of the Greek bond deal are leaking out via Reuters, and we now learn the reason for the Greek bond sell off in recent days:
•UNDER GREEK DEBT SWAP, PRIVATE SECTOR WILL GET 3% COUPON ON BONDS FROM 2012-20, 3.75% COUPON FROM 2021 ONWARDS [2021... LOL]
•PRIVATE SECTOR WILL ALSO GET A GDP-LINKED ADDITIONAL PAYMENT, CAPPED AT 1 PCT OF THE OUTSTANDING AMOUNT OF NEW BONDS [If it appears that nobody gives a rat's ass about this bullet point, it's because it's true]
•GREEK BANK RECAPITALISATION NEEDS MAY NOW BE AS MUCH AS 50 BLN EUROS-DEBT SUSTAINABILITY ANALYSIS
Which in turn explains the sell off in pre-petition Greek junior triple subordinated bonds (i.e., those held by private unconnected investors, which are subordinated to the Troika's bailout loans, to the ECB's SMP purchases, to the Public Sector bonds and to UK-law bonds in that order). With the EFSF Bill "sweetener" amounting to about 15 cents (and likely less), the fact that bondholders will receive a 3% cash coupon, a cash on cash return based on Greek bonds of 2015 trading at just 20.7 cents on the euro, indicates that investors are expecting to collect 1 cash coupon payment, and at absolute best 2, before redefault, as buying a 2015 bond now at 20.7 of par, yields a full cash return of 21 (15+3+3), thus the third coupon payment is assured not to come. And since there is a substantial upside risk premium kicker to bond buyers, in reality the investing market is saying that Greece will last at best about a year following the debt exchange (if it ever even happens) before the country redefaults.
Oh, and by the way, the fact that creditors just got even more bent over, just assures that Greece can kiss the 75% threshold for PSI acceptance goodbye. Hello CACs, and CDS trigger.
Some more just out of Reuters:
Greece will need additional relief if it is to cut its debts to 120 percent of GDP by 2020 and if it doesn't follow through on structural reforms and other measures, its debt could hit 160 percent by 2020, a debt sustainability report by the IMF, European Central Bank and European Commission shows.
The baseline scenario is that Greece will cut its debt to 129 percent of GDP in 2020 from 160 percent now, well above the targeted 120 percent, the confidential, 9-page analysis prepared for euro zone finance ministers showed.
"The results point to a need for additional debt relief from the official or private sectors to bring the debt trajectory down," said the report, dated Feb. 15 and obtained by Reuters.
The report forms the basis of discussions of euro zone ministers on the conditions under which Greece is to get further financial help from the euro zone and the IMF.
"There is a fundamental tension between the program objectives of reducing debt and improving competitiveness, in that the internal devaluation needed to restore Greece competitiveness will inevitably lead to a higher debt to GDP ratio in the near term," the report said.
"In this context, a scenario of particular concern involves internal devaluation through deeper recession (due to continued delays with structural reforms and with fiscal policy and privatisation implementation)," it said.
"This would result in a much higher debt trajectory, leaving debt as high as 160 percent of GDP in 2020. Given the risks, the Greek program may thus remain accident-prone, with questions about sustainability hanging over it," it said.
It appears nothing has been resolved. YET AGAIN
jus1,
as anything, time will tell!
gl to you
good analysis, should be taken to heart when trading and following EBIX for the next 3 months!
http://www.moneyshow.com/investing/article/1/GURU-26614/3-Software-Plays-with-Charts-in-the-Clouds/?aid=guru-26614&iid=GURU&page=1
Ebix (EBIX) is another smaller enterprise software name that’s been showing good technical strength. It’s up almost 5% so far in February, its fifth month in a row with gains.
The company makes software for the insurance industry. It’s posted a strong track record of earnings and revenue growth in recent quarters, although analysts see an income decline of 2% in 2012, to $1.41 per share.
Ebix has a market cap of around $926 million. It has decent liquidity for a small stock, moving around 467,000 shares per day on average.
However, like many small caps, it tends to trade in a volatile fashion. Its beta is currently 1.73, a sign of that volatility vs. the broader market. That means that investors need to use more caution than they would with a blue chip, which might have longer staying power in a portfolio.
While smaller stocks often pull back harder than the broader market in a downturn, they can also post bigger price gains in a bull rally. These are often stocks that should be sold to pocket gains, rather than held, during corrections.
At the moment, Ebix is still emerging from a steep base. It corrected 57% between March and October of last year, and still has some work to do before regaining previous highs.
The stock flashed a technical buy signal in December, when its ten-week line crossed above its 40-week. Since then, it has not pulled back to the ten-week for an alternate entry point. However, it appears to be digesting gains in the past two weeks, and may stop for a breather, allowing new buyers to grab shares.
The company reports earnings next month. As usual, guidance that’s better or worse than what’s expected could send the stock moving sharply in one direction or the other.
gl
no one is defending anything, as time will tell.
penny stocks are penny stocks and many dont make it, but not making it does not elude to a scam.
there are a lot of hurt feelings on the board, with many different views and agendas.
time will tell.
gl
you should ask choate.
his initial number was to idaho business review.
pretty simple.
so, why the dance?
gl
choate,
how is that possible?
the time luckydd post was out, the was closed.
i'm not sure why your running with this, and since he no longer works for the idahobusiness review.
i'm sorry, but repeating something does not make it possible.
gl to you.
smithson
all you have to do is call, and actually have a conversation!
gl to you
enjoy!
208-336-3768
gl to you guys
Time will tell.....as will both sides of an conversation will be scrutinized.
Gl luck too you.
As
Isn't it suprising the SEC hasn't taken action despite the negative rhetoric.
gl
Why everyone shocked he is not a member?
the question is not why or why not he is a member of BBB, or why or why not a politician knows of an individual is a moot point. (unless someone stated they were)
but why do people make up conversations on both sides of the arguement.
SEC will investigate and take action if deemed necessary. If your comments and concerns are valid, they will take action.
Isn't it suprising the SEC hasn't taken action despite the negative rhetoric.
gl to you zoraida!
happy investing!
CORT UP 27.06% AH TRADING as of 4:12
Suprised a few and congrats for those who held!
look forward to the next Conference call, to discuss prospectus.
gl
excellent article on NUANCE (NUAN) that shouldn't deter investors into buying into this company, but should keep an eye on the next quarter financials. As it will make or break the intermediate investors back!
http://www.fool.com/investing/general/2012/02/17/why-the-street-should-love-nuance-communications-e.aspx
gl
INTU look to be a buyer here in the near future!
lets see how it settles in after an amazing run up since september 2011!
Analysts expect higher profit for Intuit (INTU) when the company reports its second quarter results on Tuesday, February 21, 2012. The consensus estimate is calling for profit of 36 cents a share, reflecting a rise from 26 cents per share a year ago.
What to Expect:
The consensus estimate is up from three months ago when it was 35 cents, but hasn’t changed over the past month. Analysts are expecting earnings of $2.57 per share for the fiscal year.
Revenue is projected to eclipse the year-earlier total of $878 million by 15%, finishing at $1.01 billion for the quarter. For the year, revenue is expected to come in at $4.24 billion.
Trends to Watch For:
Over the last four quarters, revenue rose 7.9% on average year-over-year. The biggest boost came in the third quarter of the last fiscal year, when revenue increased 15% from the year-ago quarter.
Analyst Ratings:
The majority of analysts (66.7%) rate Intuit as a buy. This compares favorably to the analyst ratings of its nearest 10 competitors, which average 57.7% buys. Analyst sentiment has waned during the last three months.
Competitors:
Intuit is a provider of business and financial management solutions for small- and medium-sized businesses, consumers, accounting professionals, and financial institutions. One of Intuit’s main competitors in the software industry is Microsoft (MSFT). Other competitors in the information technology sector include: Netsuite (N), salesforce.com (CRM), and Nuance Communications (NUAN).
Recent Price Movement:
The stock price has increased from $51.89 on November 18, 2011 to $56.65 over the past quarter.
http://www.forbes.com/sites/narrativescience/2012/02/16/forbes-earnings-preview-intuit-2/?partner=yahootix
good job lucky!
thanks for the update, and supporting what we already know!
gl
ECYT was churning like my stomach.
showing some life during the mid day cycle!
gl
extremely strange....
below is from etrade.
EXTENDED HOURS:
Last: 4.35
Change: -6.49 (-59.87%)
Bid: 10.42 x700
Ask: 11.48 x200
below is from nasdaq.com (no change)
http://www.nasdaq.com/symbol/affy/after-hours
gl
to approve or not to approve, ode to adam!
http://www.thestreet.com/_yahoo/story/11421978/1/these-drugs-stocks-will-win-fda-approval.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA
gl
Yelp.
its an evolving business with progressive losses at the early stages of development. Is it a search engine or a yellow pages platform. the dichotomy and potential ,makes this intriguing.
http://www.bloomberg.com/news/2012-02-16/yelp-seeks-to-raise-as-much-as-100-million-in-ipo-of-user-review-website.html
similar to linkdn IPO, Opentable IPO; i do like the yelp IPO in potential, though it may open flat.
should be an interesting opportunity, as revenue and platform is more forcastable than Groupon & zynga (which i did not like).
concerns of Yelp:
http://www.bloomberg.com/video/85826512/
gl
interesting trading in ECYT.
lot of nibbling, teetering till someone flinches.
gl
downgrade of banks by MOODYS...
good read
http://finance.yahoo.com/news/moodys-may-downgrade-17-banks-003723628.html
gl
maybe next week....lol
gl
something to keep an eye on during this consolidation period.
NUAN
http://seekingalpha.com/article/370091-nuance-is-the-best-apple-in-the-bushel
gl
nice article!
not too concerned at this moment.
i was little premature yesterday.
but it still looks good!
gl
1
DRAFT 3
Medgenics To Present At LHA Life Sciences & Medical Technologies
Virtual Conference
MISGAV, Israel and SAN FRANCISCO (February 15, 2012) – Medgenics, Inc. (NYSE Amex:
MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of a novel technology for the
sustained production and delivery of therapeutic proteins in patients using their own tissue,
today announced that Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of
Medgenics, will present to investors as part of the LHA Life Sciences & Medical Technologies
Virtual Conference on Thursday, February 16, 2012, at 11:00 a.m. Eastern time.
The webcast of the Medgenics presentation will be accessible live and for 30 days at
www.medgenics.com or at the PrecisionIR event site at
http://www.investorcalendar.com/IC/CEPage.asp?ID=167330.
This virtual conference event includes 30-minute presentations with accompanying slides from
eight industry leaders, and begins at 9:00 a.m. Eastern time.
About Medgenics
Medgenics is developing and commercializing Biopump™, a proprietary tissue-based platform
technology for the sustained production and delivery of therapeutic proteins using the patient's
own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis C
and hemophilia. Medgenics believes this approach has multiple benefits compared with current
treatments, which include regular and costly injections of therapeutic proteins.
Medgenics has three long-acting protein therapy products in development based on this
technology:
· EPODURE (now completing a Phase I/II dose-ranging trial) to produce and deliver
erythropoietin for many months from a single administration, has demonstrated elevation
and stabilization of hemoglobin levels in anemic patients for six to more than 36 months;
· INFRADURE (planning to commence a Phase I/II trial in Israel in 1H12 in hepatitis C) to
produce a sustained therapeutic dose of interferon-alpha for use in the treatment of
hepatitis;
· HEMODURE is a sustained Factor VIII therapy for the prophylactic treatment of
hemophilia, now in development.
Medgenics intends to develop its innovative products and bring them to market via strategic
partnerships with major pharmaceutical and/or medical device companies.
News Release
2
In addition to treatments for anemia, hepatitis and hemophilia, Medgenics plans to develop
and/or out-license a pipeline of future Biopump™ products targeting the large and rapidly
growing global protein therapy market, which is forecast to reach $132 billion in 2013. Other
potential applications for Biopumps™ include multiple sclerosis, arthritis, pediatric growth
hormone deficiency, obesity and diabetes.
Forward-looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation
Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation)
those regarding the Company's financial position, its development and business strategy, its product candidates and
the plans and objectives of management for future operations. The Company intends that such forward-looking
statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified
by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning,
"expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other
comparable terminology. All such forward-looking statements are based on current expectations and are subject to
risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's
assumptions prove incorrect, actual results may differ materially from those included within these forward-looking
statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only
as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or
revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations
with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the forward-looking statements contained in this release may not
occur.
For further information, contact:
Medgenics, Inc.
Dr. Andrew L. Pearlman
Andrew.pearlman@medgenics.com
LHA
Anne Marie Fields
afields@lhai.com
@LHA_IR_PR
Phone: +972 4 902 8900
Phone: 212-838-3777
Abchurch Communications
Adam Michael
Joanne Shears
Jamie Hooper
jamie.hooper@abchurch-group.com
Phone: +44 207 398 7719
Religare Capital Markets (NOMAD)
Emily Staples
Phone: +44 207 444 0800
SVS Securities plc (Joint Broker)
Alex Mattey
Ian Callaway
Phone: +44 207 638 5600
3
Nomura Code Securities (Joint Broker)
Jonathan Senior
Phone: +44 207 776 1219
- Ends -
look forward to it!
gl
trading is too volatile for such minimal volume, hence my worries!
still waiting for feed back from the company, after several emails
gl
nice bounce, expect a push over $30 this week!
gl all!
NICE CONSOLIDATION.
HOLDING UP NICELY!
the support levels will be tested, and but likely climb back up leading upto the march PDUFA.
its hard to say exactly, but the share count is microscopic (relatively) move either way quickly!
gl
13.5 % down.
not suprised, as this has been a monstrous run, not suprised.
new chapter begins, and intermediate future and long term future even looks brighter!
gl
yes!
gl